Difference between revisions of "Triptorelin (Trelstar LA)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://www.pfizer.com/files/products/uspi_trelstar_la.pdf Triptorelin (Trelstar LA) package insert]</ref><ref>[http:/...") |
Warner-admin (talk | contribs) m (Text replacement - "http://hemonc.org" to "https://hemonc.org") |
||
| (19 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://www.pfizer.com/files/products/uspi_trelstar_la.pdf Triptorelin (Trelstar LA) package insert]</ref><ref>[ | + | Class/mechanism: GnRH (gonadotropin-releasing hormone)/LHRH (luteinizing hormone releasing hormone) agonist; inhibits gonadotropin secretion, decreasing circulating levels of LH (luteinizing hormone) and FSH (follicle stimulating hormone), and suppressing synthesis of ovarian and testicular steroids.<ref name="insert">[http://www.pfizer.com/files/products/uspi_trelstar_la.pdf Triptorelin (Trelstar LA) package insert]</ref><ref>[https://hemonc.org/docs/packageinsert/triptorelin.pdf Triptorelin (Trelstar LA) package insert (locally hosted backup)]</ref> |
| − | <br>Route: | + | <br>Route: IM |
| − | <br>Extravasation: | + | <br>Extravasation: n/a |
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Breast cancer]] | ||
| + | *[[Prostate cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
*[http://www.uptodate.com/contents/triptorelin-patient-drug-information Triptorelin (Trelstar LA) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/triptorelin-patient-drug-information Triptorelin (Trelstar LA) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/triptorelin-patient-drug-information Triptorelin (Trelstar LA) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/triptorelin-patient-drug-information Triptorelin (Trelstar LA) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 2000-06-15: Initial FDA approval in the palliative treatment of advanced [[Prostate cancer | prostate cancer]]. ''(Based on Heyns et al. 2003)'' | ||
| + | ==History of changes in EMA indication== | ||
| + | *1986-03-05: EURD | ||
| + | ==Also known as== | ||
| + | *'''Code names:''' AY-25650, CL-118532 | ||
| + | *'''Generic name:''' triptorelin pamoate | ||
| + | *'''Brand names:''' Decapeptyl, Detryptoreline, Diphereline, Gonapeptyl, Trelstar LA, Variopeptyl | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drugs]] | ||
| + | [[Category:Intramuscular medications]] | ||
| + | |||
| + | [[Category:Antiandrogens]] | ||
| + | [[Category:GnRH agonists]] | ||
| + | |||
| + | [[Category:Breast cancer medications]] | ||
| + | [[Category:Prostate cancer medications]] | ||
| + | |||
| + | [[Category:FDA approved in 2000]] | ||
| + | [[Category:EMA approved in 1986]] | ||
| + | [[Category:WHO Essential Cancer Medicine]] | ||
Latest revision as of 19:30, 23 June 2024
General information
Class/mechanism: GnRH (gonadotropin-releasing hormone)/LHRH (luteinizing hormone releasing hormone) agonist; inhibits gonadotropin secretion, decreasing circulating levels of LH (luteinizing hormone) and FSH (follicle stimulating hormone), and suppressing synthesis of ovarian and testicular steroids.[1][2]
Route: IM
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 2000-06-15: Initial FDA approval in the palliative treatment of advanced prostate cancer. (Based on Heyns et al. 2003)
History of changes in EMA indication
- 1986-03-05: EURD
Also known as
- Code names: AY-25650, CL-118532
- Generic name: triptorelin pamoate
- Brand names: Decapeptyl, Detryptoreline, Diphereline, Gonapeptyl, Trelstar LA, Variopeptyl